(Adnkronos) - Con un’incidenza di 0.5 - 4.2 casi per milione di persone e una prevalenza tra i 10-14 casi per milione, la granulomatosi eosinofilica con poliangite (Egpa) è una malattia rara che interessa i vasi sanguigni di piccole e medie dimensioni, coinvolgendo più organi. È una malattia subdola e per la diagnosi ci possono volere tra i 7 e i 10 anni. Dell’Egpa e dei nuovi approcci terapeutici se ne è parlato all’incontro stampa organizzato da Gsk a Milano, “Egpa: opportunità di trattamento con mepolizumab e ruolo dello pneumologo”.
Category
🗞
NewsTranscript
00:00With an incidence of 0.5 and 4.2 cases per million people and a prevalence between 10 and 14 cases per million,
00:12esophilic granulomatosis with polyangiitis and GPA is a rare disease that affects small and medium-sized blood vessels involving several organs.
00:23It is a subdued disease and for this, for diagnosis, it can take between 7 and 10 years.
00:28Alarm bell, the excessive increase of eosinophils, cells of the immune system.
00:34They are usually patients who have asthma for years, they have chronic rhinosinusitis, often with polyposis, they are also operated 2-3 times.
00:44At a certain point, there is an important increase in eosinophils and one of the important things to say is to always check the eosinophils,
00:56a hemochrome with the formula, to see if they have increased in normal form.
01:02Because if they increase in a really important way, like more than 5, 10,000, 15,000, they can then infiltrate the organs and then there becomes the problem.
01:13The GPA, already known as Churg-Strauss syndrome, was dedicated to the EGPA press conference,
01:20treatment opportunities with mepolizumab and the role of the pneumologist, organized in Milan by GSK.
01:27An appointment in which new therapeutic approaches were also discussed.
01:31The advent of new therapies, extremely targeted, such as mepolizumab, which blocks circulating interleukin-5,
01:38allows us to target the path of type 2 inflammation in an extremely specific way,
01:44rapidly reducing the circulating and tissue eosinophil,
01:48therefore checking all those eosinophilic manifestations that characterize the relapses that these patients have.
01:55This allows us to significantly reduce the exposure to cortisone and improve the quality of life of these patients.
02:04The impact of the EGPA on the life of patients involves both the physical and psychological level,
02:09it is essential for them to have a perspective of care.
02:12Today patients can live a life as normal as possible,
02:17no matter how difficult the term may be,
02:21and certainly they have a very different therapeutic horizon, a horizon of care, compared to a time.